Acrivon Therapeutics, Inc. financial data

Symbol
ACRV on Nasdaq
Industry
Pharmaceutical Preparations
Location
480 Arsenal Way, Suite 100, Watertown, Massachusetts
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.4 K %
Debt-to-equity 10.3 %
Return On Equity -49.7 % +15.9%
Return On Assets -45 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.6 M shares +3.27%
Common Stock, Shares, Outstanding 22.6 M shares +3.27%
Common Stock, Value, Issued 23 K USD +4.55%
Weighted Average Number of Shares Outstanding, Basic 22.6 M shares +3.06%
Weighted Average Number of Shares Outstanding, Diluted 22.6 M shares +3.06%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.5 M USD +17.6%
General and Administrative Expense 6.2 M USD +33.7%
Operating Income (Loss) -70.4 M USD -76.7%
Nonoperating Income (Expense) 1.18 M USD -27.8%
Net Income (Loss) Attributable to Parent -64.1 M USD -74.7%
Earnings Per Share, Basic -2.89 USD/shares +28.8%
Earnings Per Share, Diluted -2.89 USD/shares +28.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24.6 M USD -10.5%
Assets, Current 112 M USD -9.54%
Property, Plant and Equipment, Net 3.41 M USD +71.1%
Operating Lease, Right-of-Use Asset 4.21 M USD -8.17%
Assets 121 M USD -29.2%
Accounts Payable, Current 2.06 M USD +49.6%
Liabilities, Current 9.04 M USD +59.1%
Operating Lease, Liability, Noncurrent 3.5 M USD -13.5%
Liabilities 12.5 M USD +28.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -70 K USD -878%
Retained Earnings (Accumulated Deficit) -133 M USD -14.2%
Stockholders' Equity Attributable to Parent 108 M USD -32.7%
Liabilities and Equity 121 M USD -29.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.1 M USD -50.4%
Net Cash Provided by (Used in) Financing Activities -172 K USD
Net Cash Provided by (Used in) Investing Activities 5.85 M USD -37.3%
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 22.6 M shares +3.27%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.4 M USD -462%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25 M USD -10.2%
Operating Lease, Liability 4.45 M USD -7.13%
Depreciation 635 K USD +43%
Payments to Acquire Property, Plant, and Equipment 815 K USD +3160%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -16.5 M USD -30.2%
Lessee, Operating Lease, Liability, to be Paid 5.19 M USD -10.6%
Property, Plant and Equipment, Gross 4.59 M USD +80.8%
Operating Lease, Liability, Current 944 K USD +27.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.34 M USD +18.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.31 M USD +18.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 749 K USD -27.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.2 M USD +3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 404 K USD -66.3%
Operating Lease, Payments 300 K USD 0%
Additional Paid in Capital 241 M USD +5.11%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 12.3 M USD +157%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%